PO.ET09.06 · 实验与分子治疗
NOVO-111：一种为改善肿瘤靶向性和耐受性而设计的大环药物偶联物
NOVO-111: A macrocycle drug conjugate engineered for improved tumor targeting and tolerability
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景：NOVO-111 是一种新型钆(III)-德克萨卟啉-铂(IV)配合物，被设计为奥沙利铂（1,2-二氨基环己烷-铂(II)草酸盐）的肿瘤亲和性前药。德克萨卟啉基团赋予其氧化还原活性和肿瘤定位特性，旨在改善铂的递送并降低全身毒性。临床前数据提示，NOVO-111 不仅作为抗肿瘤药物更为有效，而且比奥沙利铂具有更好的耐受性。
方法：在荷 HCT-116 结直肠癌异种移植瘤（KRAS^G13D^）的裸鼠中进行了药代动力学（PK）、生物分布和药效学（PD）研究。动物静脉给予奥沙利铂（4 mg/kg，MTD）或等摩尔剂量（17 mg/kg）以及三倍高剂量（50 mg/kg；≤MTD）的 NOVO-111。对血浆和组织样本进行铂（Pt）水平分析，并通过免疫印迹检测 p53/p21 通路的激活情况。
结果：给药后，约 97% 的 NOVO-111 在 2 小时内与血浆结合。一小部分游离 Pt 组分（以 NOVO-111 形式）缓慢衰减（t₁/₂ = 11.4 h），提示全身暴露时间延长。与奥沙利铂相比，NOVO-111 在血浆、肝、肾、心脏、卵巢和睾丸中产生了更高的 Pt 蓄积（1.5-7 倍），而在等摩尔剂量下，肿瘤和回肠的暴露相当。在 50 mg/kg 剂量下，正常组织中的 Pt 水平升高约 3 倍，而肿瘤中升高 >5 倍，这与德克萨卟啉介导的选择性蓄积一致。在体内，NOVO-111 较等耐受剂量的奥沙利铂实现了更强的 HCT-116 肿瘤生长抑制，且未增加全身毒性。然而，两种药物均诱导了相当程度的肿瘤 p53/p21 上调，表明使暴露增强和 Pt(II) 持续释放的 PK 特征也可能驱动了 NOVO-111 的更优疗效。
结论：NOVO-111 展现出独特的 PK 和肿瘤靶向特性，相较于奥沙利铂可带来更佳的治疗表现。Pt(II) 的持久存在、增强的肿瘤蓄积以及良好的耐受性共同支持其作为新一代铂类治疗药物用于结直肠癌及其他实体瘤的推进。这些发现凸显了德克萨卟啉引导递送平台在克服传统铂类化疗长期局限性方面的转化潜力。
查看英文原文 English abstract
Background: NOVO-111 is a novel gadolinium(III) texaphyrin-platinum(IV) complex designed as a tumor-affinic prodrug of oxaliplatin (1,2-diaminocyclohexane-platinum(II) oxalate). The texaphyrin moiety confers redox activity and tumor localization properties intended to improve platinum delivery and reduce systemic toxicity. Preclinical data suggest NOVO-111 is not only more effective as an antitumor agent but also better tolerated than oxaliplatin.
Methods: Pharmacokinetic (PK), biodistribution, and pharmacodynamic (PD) studies were performed in nude mice bearing HCT-116 colorectal xenografts (KRAS^G13D^). Animals received intravenous oxaliplatin (4 mg/kg, MTD) or equimolar (17 mg/kg) and three-fold higher (50 mg/kg; ≤MTD) doses of NOVO-111. Plasma and tissue samples were analyzed for platinum (Pt) levels and for activation of the p53/p21 pathway by immunoblotting.
Results: Following administration, ~97% of NOVO-111 became plasma bound over 2 hours. A small free Pt fraction (as NOVO-111) decayed slowly (t₁/₂ = 11.4 h), suggesting prolonged systemic exposure. Compared to oxaliplatin, NOVO-111 produced higher Pt accumulation (1.5-7-fold) in plasma, liver, kidney, heart, ovary, and testes, while tumor and ileum exposure were comparable at equimolar doses. At 50 mg/kg, Pt levels increased ~3-fold in normal tissues but >5-fold in tumor, consistent with selective texaphyrin-mediated accumulation. In vivo, NOVO-111 achieved greater HCT-116 tumor growth inhibition than an equi-tolerated dose of oxaliplatin, without increased systemic toxicity. Both agents, however, induced comparable tumor p53/p21 upregulation. indicating that PK features resulting in enhanced exposure and sustained Pt(II) release also likely drive NOVO-111's superior efficacy.
Conclusions: NOVO-111 displays unique PK and tumor-targeting characteristics that yield improved therapeutic performance relative to oxaliplatin. Prolonged Pt(II) persistence, enhanced tumor accumulation, and favorable tolerability together support its advancement as a next-generation platinum-based therapeutic for colorectal and other solid tumors. These findings underscore the translational potential of texaphyrin-guided delivery platforms to overcome long-standing limitations of traditional platinum chemotherapy.
利益披露 Disclosure
J. F. Aramubla,
Innovotex inc. Employment, g., Board of Directors, non-salaried role), Stock.
G. He, None..
G. Thiabaud, None..
K. Shelton, None..
L. J. Segura, None.
J. L. Sessler,
INNOVOTEX INC. Stock, Other Business Ownership, Co-founder and director.